UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy

Annals of hematology, 2021-09, Vol.100 (9), p.2303-2310

2021

Link zum Volltext

Verfügbarkeit prüfen

Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy

Leukemia, 2020-12, Vol.34 (12), p.3420-3425

2020

Link zum Volltext

Verfügbarkeit prüfen

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e004475

2022

Link zum Volltext

Verfügbarkeit prüfen

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Cancer medicine (Malden, MA), 2021-05, Vol.10 (10), p.3214-3223

2021

Link zum Volltext

Verfügbarkeit prüfen

Organization of a reference haemophilia unit and its change of activity during the COVID‐19 pandemic

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e473-e475

2021

Link zum Volltext

Verfügbarkeit prüfen

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation

Leukemia & lymphoma, 2019-01, Vol.60 (1), p.142-150

2019

Link zum Volltext

Verfügbarkeit prüfen

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

EJHaem, 2023-11, Vol.4 (4), p.1081-1088

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Biomarker research, 2021-05, Vol.9 (1), p.37-37, Article 37

2021

Link zum Volltext

Verfügbarkeit prüfen

Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivo. Perspectiva actual tras una década de tratamiento

Medicina clínica, 2022-04, Vol.158 (7), p.327-332

2022

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Journal of clinical oncology, 2021-06, Vol.39 (18), p.JCO2003175-1970

2021

Link zum Volltext

Verfügbarkeit prüfen

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The New England journal of medicine, 2022-12, Vol.387 (24), p.2220-2231

2022

Link zum Volltext

Verfügbarkeit prüfen

CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma

The Lancet. Haematology, 2023-12, Vol.10 (12), p.e951-e952

2023

Link zum Volltext

Verfügbarkeit prüfen

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment

Medicina clinica, 2022-04, Vol.158 (7), p.327

2022

Link zum Volltext

Verfügbarkeit prüfen

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment

Medicina clínica (English ed.), 2022-04, Vol.158 (7), p.327-332

2022

Link zum Volltext

Verfügbarkeit prüfen

From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia

Cancer treatment reviews, 2023-11, Vol.120, p.102619-102619, Article 102619

2023

Link zum Volltext

Verfügbarkeit prüfen

5213 RELATIONSHIP BETWEEN CYTOKINE RELEASE SYNDROME AND ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN HEMATOLOGIC NEOPLASMS

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Link zum Volltext

Verfügbarkeit prüfen

PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.3783-3784

2022

Link zum Volltext

Verfügbarkeit prüfen

FC072: Acute Kidney Injury and Chimeric Antigen Receptor (CAR)-T Therapy in Haematologic Neoplasias: The Importance of Kidney Disease

Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Hematology
(26)
Humans
(19)
Oncology
(16)
Immunology
(13)
Lymphoma
(10)
Transplantation
(8)
Adult
(7)
Chemotherapy
(7)
Chimeric Antigen Receptors
(7)
Lymphocytes T
(7)
Male
(7)
Cell Therapy
(6)
Diffuse Large B-Cell Lymphoma
(6)
Lymphocytes B
(6)
Patients
(6)
B-Cell Lymphoma
(5)
Female
(5)
Immunotherapy, Adoptive - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy

Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Organization of a reference haemophilia unit and its change of activity during the COVID‐19 pandemic

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation

P1151: BENDAMUSTINE‐CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR‐T for Relapsed/Refractory B‐NHL

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR‐T for Relapsed/Refractory Large B‐cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR‐T Product Use

Case report: Cytokine hemoadsorption in a case of hemophagocytic lymphohistiocytosis secondary to extranodal NK/T-cell lymphoma

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivo. Perspectiva actual tras una década de tratamiento

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment

Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia

5213 RELATIONSHIP BETWEEN CYTOKINE RELEASE SYNDROME AND ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN HEMATOLOGIC NEOPLASMS

PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

FC072: Acute Kidney Injury and Chimeric Antigen Receptor (CAR)-T Therapy in Haematologic Neoplasias: The Importance of Kidney Disease

Suchergebnisse filtern